Dermata Therapeutics Warrant
DRMAW
5 hedge funds and large institutions have $7.48K invested in Dermata Therapeutics Warrant in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
1.49% more ownership
Funds ownership: 1.1% → 2.59% (+1.5%)
44% less capital invested
Capital invested by funds: $13.2K → $7.48K (-$5.76K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$201 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$198 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14 |
| 2 |
TSS
Two Sigma Securities
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $7.02K | – | – | – |
|
|
TSS
2
Two Sigma Securities
New York
| $232 | -$2 | -100 | -0.8% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $190 | +$198 | +10,723 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $34 | -$14 | -737 | -28% |
|
|
VF
5
Virtu Financial
New York
| – | +$201 | +10,856 | New |
|
DRMAW Hedge Fund Activity: Q2 2025 in Review
5 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q2 2025, worth a combined $7.48K — down 44% from $13.2K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new DRMAW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $201. The largest seller was UBS Group, cutting an estimated $14.
- 5 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $7.48K of Dermata Therapeutics Warrant stock for Q2 2025, down 44% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics Warrant positions in Q2 2025 and 0 closed out, a net change of +2 holders.
- The largest Dermata Therapeutics Warrant buyer in Q2 2025 was Virtu Financial, an estimated $201 added.
- The largest Dermata Therapeutics Warrant seller in Q2 2025 was UBS Group, an estimated $14 sold.
Based on aggregated 13F filings for Q2 2025.